Pfizer (United States)-ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2021

  1. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with cd-33 positive acute myeloid leukaemia in spain

    ClinicoEconomics and Outcomes Research, Vol. 13, pp. 263-277

2020

  1. Disease features associated with a low disease impact in patients with psoriatic arthritis: Results of a cross-sectional multicenter study

    Arthritis Research and Therapy, Vol. 22, Núm. 1

2019

  1. Very low disease activity, DAPSA remission, and impact of disease in a Spanish population with psoriatic arthritis

    Journal of Rheumatology, Vol. 46, Núm. 7, pp. 710-715

2017

  1. Minimal disease activity and impact of disease in psoriatic arthritis: A Spanish cross-sectional multicenter study

    Arthritis Research and Therapy, Vol. 19, Núm. 1